Chinahealthwise (00348) announced its mid-term performance for 2024, with revenue of HKD 60.932 million, a decrease of approximately 24.61% year-on-year...
According to the Zhitong Finance APP, Chinahealthwise (00348) announced its mid-term performance for 2024, with revenue of HKD 60.932 million, a decrease of approximately 24.61% year-on-year; a net loss of HKD 28.663 million, a narrowing of approximately 10.04% year-on-year; and a loss per share of HKD 3.72.
The announcement stated that the reduction in losses was mainly due to a decrease in gross profit from approximately HKD 34 million in the corresponding period to approximately HKD 20 million in the current period; a decrease in impairment losses on receivables from approximately HKD 28 million in the corresponding period to approximately HKD 6 million in the current period; and a net impact on fair value losses from approximately HKD 5 million in the corresponding period to approximately HKD 0.1 million in the current period.